CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. [electronic resource]
Producer: 20081104Description: 1921-6 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- biosynthesis
- CD5 Antigens -- biosynthesis
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Phenotype
- Prednisone -- administration & dosage
- Proto-Oncogene Proteins c-bcl-2 -- biosynthesis
- Rituximab
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.